Which has better earnings and valuation, SKYE or RADX?

Radiopharm Theranostics has higher revenue and earnings than Skye Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.27 N/A Radiopharm Theranostics $2.35M 13.60 -$24.83M N/A N/A

Is SKYE or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -329.08% -201.79% Radiopharm Theranostics N/A N/A N/A

Does the media prefer SKYE or RADX?

In the previous week, Skye Bioscience and Skye Bioscience both had 3 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.96 beat Skye Bioscience's score of 0.62 indicating that Radiopharm Theranostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SKYE or QNCX?

Skye Bioscience is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Skye Bioscience N/A N/A -$55.92M -$1.27 N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is SKYE or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -329.08% -201.79% Quince Therapeutics N/A N/A -133.84%

Does the media refer more to SKYE or QNCX?

In the previous week, Quince Therapeutics had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for Skye Bioscience. Quince Therapeutics' average media sentiment score of 0.93 beat Skye Bioscience's score of 0.62 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SKYE or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Skye Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Skye Bioscience N/A -329.08% -201.79% Actinium Pharmaceuticals N/A -100.85% -47.89%

Does the media prefer KYNB or SKYE?

In the previous week, Skye Bioscience had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Skye Bioscience and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.94 beat Skye Bioscience's score of 0.62 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Skye Bioscience (SKYE) Competitors

$1.75 -0.03 (-1.41%)

As of 01:11 PM Eastern

Compare

SKYE vs. MDXH, RADX, QNCX, ATNM, and KYNB

Should you buy Skye Bioscience stock or one of its competitors? Skye Bioscience's main competitors and comparable companies include MDxHealth (MDXH), Radiopharm Theranostics (RADX), Quince Therapeutics (QNCX), Actinium Pharmaceuticals (ATNM), and Kyntra Bio (KYNB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Skye Bioscience compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

In the previous week, Skye Bioscience had 2 more articles in the media than MDxHealth. MarketBeat recorded 3 mentions for Skye Bioscience and 1 mentions for MDxHealth. MDxHealth's average media sentiment score of 1.87 beat Skye Bioscience's score of 0.62 indicating that MDxHealth is being referred to more favorably in the media.

Company	Overall Sentiment
MDxHealth	Very Positive
Skye Bioscience	Positive

MDxHealth has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$114.02M	0.32	-$33.52M	-$0.72	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.27	N/A

MDxHealth presently has a consensus target price of $2.17, indicating a potential upside of 198.40%. Skye Bioscience has a consensus target price of $64.00, indicating a potential upside of 3,557.14%. Given Skye Bioscience's higher possible upside, analysts clearly believe Skye Bioscience is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

21.1% of Skye Bioscience shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 6.2% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Skye Bioscience has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Skye Bioscience	N/A	-329.08%	-201.79%

MDxHealth has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.97, meaning that its stock price is 197% more volatile than the broader market.

Summary

MDxHealth beats Skye Bioscience on 8 of the 15 factors compared between the two stocks.

How does Skye Bioscience compare to Radiopharm Theranostics?

Skye Bioscience (NASDAQ:SKYE) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Radiopharm Theranostics' return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
Radiopharm Theranostics	N/A	N/A	N/A

Skye Bioscience presently has a consensus price target of $64.00, indicating a potential upside of 3,557.14%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 397.74%. Given Skye Bioscience's higher probable upside, research analysts clearly believe Skye Bioscience is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Skye Bioscience has a beta of 2.97, meaning that its stock price is 197% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

21.1% of Skye Bioscience shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Skye Bioscience and Skye Bioscience both had 3 articles in the media. Radiopharm Theranostics' average media sentiment score of 0.96 beat Skye Bioscience's score of 0.62 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Radiopharm Theranostics has higher revenue and earnings than Skye Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.27	N/A
Radiopharm Theranostics	$2.35M	13.60	-$24.83M	N/A	N/A

Summary

Radiopharm Theranostics beats Skye Bioscience on 6 of the 10 factors compared between the two stocks.

How does Skye Bioscience compare to Quince Therapeutics?

Skye Bioscience (NASDAQ:SKYE) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Skye Bioscience presently has a consensus target price of $64.00, suggesting a potential upside of 3,557.14%. Quince Therapeutics has a consensus target price of $260.00, suggesting a potential upside of 691.48%. Given Skye Bioscience's higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42

Skye Bioscience has a beta of 2.97, indicating that its stock price is 197% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Quince Therapeutics' return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
Quince Therapeutics	N/A	N/A	-133.84%

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Quince Therapeutics had 2 more articles in the media than Skye Bioscience. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for Skye Bioscience. Quince Therapeutics' average media sentiment score of 0.93 beat Skye Bioscience's score of 0.62 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Skye Bioscience is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.27	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Summary

Quince Therapeutics beats Skye Bioscience on 9 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to Actinium Pharmaceuticals?

Skye Bioscience (NASDAQ:SKYE) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Skye Bioscience has a beta of 2.97, indicating that its stock price is 197% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Actinium Pharmaceuticals has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.27	N/A
Actinium Pharmaceuticals	$35.09M	0.91	-$48.82M	$0.36	2.82

Actinium Pharmaceuticals' return on equity of -100.85% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-329.08%	-201.79%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

In the previous week, Skye Bioscience had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 3 mentions for Skye Bioscience and 0 mentions for Actinium Pharmaceuticals. Skye Bioscience's average media sentiment score of 0.62 beat Actinium Pharmaceuticals' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Skye Bioscience	Positive
Actinium Pharmaceuticals	Neutral

21.1% of Skye Bioscience shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 6.2% of Skye Bioscience shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Skye Bioscience currently has a consensus target price of $64.00, suggesting a potential upside of 3,557.14%. Actinium Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 392.61%. Given Skye Bioscience's higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Skye Bioscience and Actinium Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Skye Bioscience compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Skye Bioscience (NASDAQ:SKYE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Kyntra Bio currently has a consensus target price of $32.50, suggesting a potential upside of 308.29%. Skye Bioscience has a consensus target price of $64.00, suggesting a potential upside of 3,557.14%. Given Skye Bioscience's higher possible upside, analysts plainly believe Skye Bioscience is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Kyntra Bio has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	5.01	$183.45M	$45.30	0.18
Skye Bioscience	N/A	N/A	-$55.92M	-$1.27	N/A

In the previous week, Skye Bioscience had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 3 mentions for Skye Bioscience and 2 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.94 beat Skye Bioscience's score of 0.62 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Skye Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has a net margin of 2,199.13% compared to Skye Bioscience's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Skye Bioscience	N/A	-329.08%	-201.79%

Kyntra Bio has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 2.97, indicating that its share price is 197% more volatile than the broader market.

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Kyntra Bio beats Skye Bioscience on 11 of the 15 factors compared between the two stocks.

Get Skye Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SKYE vs. The Competition

Export

Metric	Skye Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.75M	$3.92B	$7.13B	$12.81B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.17	11.77	272.85	25.45
Price / Sales	N/A	1,393.83	685.78	122.48
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.35	16.75	11.02	6.33
Net Income	-$55.92M	-$22.71M	$3.47B	$349.46M
7 Day Performance	-19.35%	2.15%	0.94%	-0.29%
1 Month Performance	-61.52%	12.31%	7.93%	4.18%
1 Year Performance	-93.75%	53.90%	23.74%	14.53%

Skye Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SKYE Skye Bioscience	2.9647 of 5 stars	$1.75 -1.4%	$64.00 +3,557.1%	-93.7%	$7.75M	N/A	N/A	11
MDXH MDxHealth	2.4702 of 5 stars	$0.79 +6.4%	$2.17 +174.7%	-79.7%	$36.69M	$107.88M	N/A	300
RADX Radiopharm Theranostics	4.0777 of 5 stars	$2.48 +1.6%	$11.00 +343.5%	-56.1%	$35.28M	$2.35M	N/A	N/A	Short Interest Decrease
QNCX Quince Therapeutics	2.7762 of 5 stars	$30.93 -7.6%	$260.00 +740.6%	-89.5%	$34.05M	N/A	N/A	60	News Coverage
ATNM Actinium Pharmaceuticals	1.8729 of 5 stars	$1.08 +2.9%	$5.00 +363.0%	-43.3%	$33.96M	$35.09M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SKYE) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Skye Bioscience (SKYE) Competitors

SKYE vs. MDXH, RADX, QNCX, ATNM, and KYNB

How does Skye Bioscience compare to MDxHealth?

Summary

How does Skye Bioscience compare to Radiopharm Theranostics?

Summary

How does Skye Bioscience compare to Quince Therapeutics?

Summary

How does Skye Bioscience compare to Actinium Pharmaceuticals?

Summary

How does Skye Bioscience compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Skye Bioscience (SKYE) Competitors

SKYE vs. MDXH, RADX, QNCX, ATNM, and KYNB

How does Skye Bioscience compare to MDxHealth?

Does the media favor MDXH or SKYE?

Which has higher valuation and earnings, MDXH or SKYE?

Do analysts recommend MDXH or SKYE?

Do insiders & institutionals believe in MDXH or SKYE?

Is MDXH or SKYE more profitable?

Which has more risk & volatility, MDXH or SKYE?

Summary

How does Skye Bioscience compare to Radiopharm Theranostics?

Is SKYE or RADX more profitable?

Do analysts rate SKYE or RADX?

Which has more volatility & risk, SKYE or RADX?

Do institutionals and insiders hold more shares of SKYE or RADX?

Does the media prefer SKYE or RADX?

Which has better earnings and valuation, SKYE or RADX?

Summary

How does Skye Bioscience compare to Quince Therapeutics?

Do analysts prefer SKYE or QNCX?

Which has more risk and volatility, SKYE or QNCX?

Is SKYE or QNCX more profitable?

Do insiders & institutionals hold more shares of SKYE or QNCX?

Does the media refer more to SKYE or QNCX?

Which has higher earnings and valuation, SKYE or QNCX?

Summary

How does Skye Bioscience compare to Actinium Pharmaceuticals?

Which has more volatility & risk, SKYE or ATNM?

Which has better earnings and valuation, SKYE or ATNM?

Is SKYE or ATNM more profitable?

Does the media prefer SKYE or ATNM?

Do institutionals and insiders hold more shares of SKYE or ATNM?

Do analysts recommend SKYE or ATNM?

Summary

How does Skye Bioscience compare to Kyntra Bio?

Do analysts recommend KYNB or SKYE?

Which has stronger earnings & valuation, KYNB or SKYE?

Does the media prefer KYNB or SKYE?

Is KYNB or SKYE more profitable?

Which has more risk & volatility, KYNB or SKYE?

Do insiders & institutionals hold more shares of KYNB or SKYE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE vs. The Competition

Skye Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools